Oppenheimer Holdings, Inc. upgraded shares of NeuroDerm Ltd. (NASDAQ:NDRM) from a market perform rating to an outperform rating in a report published on Wednesday morning, MarketBeat Ratings reports. The firm currently has $42.00 price objective on the biotechnology company’s stock.
A number of other equities research analysts have also recently commented on NDRM. Roth Capital set a $33.00 price objective on shares of NeuroDerm and gave the stock a buy rating in a research note on Saturday, April 1st. Citigroup Inc. cut shares of NeuroDerm from an outperform rating to a market perform rating in a research note on Tuesday, March 7th. CIBC reaffirmed a market perform rating on shares of NeuroDerm in a research note on Tuesday, March 7th. Zacks Investment Research cut shares of NeuroDerm from a buy rating to a hold rating in a research note on Tuesday, February 14th. Finally, Jefferies Group LLC reaffirmed a buy rating and set a $42.00 price objective on shares of NeuroDerm in a research note on Monday, April 24th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $43.50.
NeuroDerm (NDRM) opened at 29.45 on Wednesday. The company’s market capitalization is $775.65 million. The firm has a 50 day moving average of $24.39 and a 200-day moving average of $24.31. NeuroDerm has a 52-week low of $15.12 and a 52-week high of $30.75.
NeuroDerm (NASDAQ:NDRM) last issued its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.13. Equities analysts expect that NeuroDerm will post ($2.02) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “NeuroDerm Ltd. (NDRM) Upgraded to “Outperform” at Oppenheimer Holdings, Inc.” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2654522/neuroderm-ltd-ndrm-upgraded-to-outperform-at-oppenheimer-holdings-inc.html.
Large investors have recently modified their holdings of the company. Oppenheimer & Co. Inc. purchased a new stake in shares of NeuroDerm during the first quarter worth approximately $223,000. Nationwide Fund Advisors purchased a new stake in shares of NeuroDerm during the first quarter worth approximately $226,000. HighTower Advisors LLC purchased a new stake in shares of NeuroDerm during the first quarter worth approximately $242,000. NJ State Employees Deferred Compensation Plan purchased a new stake in shares of NeuroDerm during the first quarter worth approximately $266,000. Finally, Tudor Investment Corp Et Al purchased a new stake in shares of NeuroDerm during the fourth quarter worth approximately $222,000. 50.24% of the stock is currently owned by institutional investors and hedge funds.
NeuroDerm Company Profile
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.